X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Pfizer Fact Sheet, Pfizer Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Pfizer Fact Sheet   (PFIZ)

Here is the latest financial fact sheet of Pfizer. For more details, see the Pfizer quarterly results and Pfizer share price and chart. For a sector overview, read our pharmaceuticals sector report.

PFIZER Price History

Price Rs 1,773.6
Mkt Cap Rs m 81,142
Vol '000 20.9
P/E X 24.1
P/CF X 23.4
EPS (TTM) Rs 73.6
% ch % -1.5
No. of shares m 45.75
% ch week % 2.9
% ch 1-mth % 3.8
% ch 12-mth % -6.0
52 week H/L Rs 2,055.0/1,625.0
(As on Jun 23, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

PFIZER Financials

No. of Mths
Year Ending
12
Mar-12
12
Mar-13
12
Mar-14
12
Mar-15
12
Mar-16
5-Yr Chart
Click to enlarge
PFIZER EQUITY SHARE DATA
High Rs1,6361,4101,7792,3252,724 
Low Rs1,0729999851,1751,611 
Sales per share (Unadj.) Rs366.4351.5372.6405.1440.9 
Earnings per share (Unadj.) Rs61.9168.674.015.348.7 
Diluted earnings per shareRs40.4110.048.315.348.7 
Cash flow per share (Unadj.) Rs65.1171.376.743.975.8 
Dividends per share (Unadj.) Rs12.5032.50360.0012.5015.00 
Adj. dividends per shareRs8.1521.20234.8112.5015.00 
Dividend yield (eoy) %0.92.726.00.70.7 
Book value per share (Unadj.) Rs437.2567.8220.6431.3462.9 
Adj. book value per shareRs285.2370.4143.9431.3462.9 
Shares outstanding (eoy) m29.8429.8429.8445.7545.75 
Bonus/Rights/Conversions  ---A- 
Price / Sales ratio x3.73.43.74.34.9 
Avg P/E ratio x21.97.118.7114.744.5 
P/CF ratio (eoy) x20.87.018.039.928.6 
Price / Book Value ratio x3.12.16.34.14.7 
Dividend payout %20.219.3486.481.930.8 
Avg Mkt Cap Rs m40,40335,93641,23980,06399,163 
No. of employees `0003.22.82.4NA2.9 
Total wages/salary Rs m1,9282,1111,9182,3642,758 
Avg. sales/employee Rs Th3,469.73,752.64,600.0NM6,981.7 
Avg. wages/employee Rs Th611.9755.3793.4NM954.5 
Avg. net profit/employee Rs Th585.91,800.4913.8NM771.1 
PFIZER INCOME DATA
Net Sales Rs m10,93310,48811,11818,53320,170 
Other income Rs m9271,0521,094674857 
Total revenues Rs m11,86011,54112,21219,20721,028 
Gross profit Rs m1,9531,8272,3853,8304,310 
Depreciation Rs m9680801,3111,239 
Interest Rs m62485 
Profit before tax Rs m2,7792,7973,3963,1853,923 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m-44,1410-1,11099 
Tax Rs m9291,9061,1871,3771,794 
Profit after tax Rs m1,8465,0322,2096982,228 
Gross profit margin %17.917.421.520.721.4 
Effective tax rate %33.468.135.043.245.7 
Net profit margin %16.948.019.93.811.0 
PFIZER BALANCE SHEET DATA
Current assets Rs m13,30818,0446,86012,52016,299 
Current liabilities Rs m2,5103,5093,0346,0857,594 
Net working cap to sales %98.8138.634.434.743.2 
Current ratio x5.35.12.32.12.1 
Inventory Days Days6157507665 
Debtors Days Days4749573226 
Net fixed assets Rs m3192592329,5698,622 
Share capital Rs m298298298458458 
"Free" reserves Rs m12,74916,6466,28619,27320,722 
Net worth Rs m13,04716,9446,58419,73021,180 
Long term debt Rs m0002525 
Total assets Rs m15,81620,5959,76726,13729,137 
Interest coverage x472.01,166.2944.3414.6755.5 
Debt to equity ratio x00000 
Sales to assets ratio x0.70.51.10.70.7 
Return on assets %11.724.422.72.77.7 
Return on equity %14.129.733.53.510.5 
Return on capital %21.341.051.610.519.0 
Exports to sales %0.20.100.10.1 
Imports to sales %9.48.99.423.117.5 
Exports (fob) Rs m17125912 
Imports (cif) Rs m1,0309321,0504,2743,526 
Fx inflow Rs m2211558311752 
Fx outflow Rs m1,1601,2659,4314,383140 
Net fx Rs m-939-1,110-9,348-4,266-88 
PFIZER CASH FLOW
From Operations Rs m 245 -160 1,325 1,135 3,436 
From Investments Rs m 2,775 6,259 1,027 -888 -6,991 
From Financial Activity Rs m -141 -432 -13,602 -14 -619 
Net Cashflow Rs m 2,879 5,667 -11,251 233 -4,174 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 0.0%
Foreign collaborators 63.9%
Indian inst/Mut Fund 7.5%
FIIs 4.9%
ADR/GDR 0.0%
Free float 23.7%
Shareholders 85,207
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Pfizer Centre, Patel Estate, S. V. Road, Jogeshwari (W), Mumbai - 400 102
E-MAIL prajeet.nair@pfizer.com WEB www.pfizerindia.com
TELEPHONE (022) 6693 2000 FAX (022) 2678 4569
SECTOR PHARMACEUTICALS GROUP M N C
TR AGENT Karvy Computershare, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR B S R & Co. LLP
CHM: R. A. Shah COMP SEC: Prajeet Nair YEAR OF INC: 1950 BSE CODE: 500680 FV (Rs): 10 DIV YIELD (%): 0.8

More Pharmaceuticals Company Fact Sheets:   GSK PHARMA  FDC LTD.  ASTRAZENECA PHARMA  LUPIN LTD  FRESENIUS KABI ONCO.  

Compare PFIZER With:   GSK PHARMA  FDC LTD.  ASTRAZENECA PHARMA  LUPIN LTD  FRESENIUS KABI ONCO.  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Share Markets End the Week on a Dull Note(RoundUp)

Global financial markets ended the week on a dull note. This was on back of the Federal Reserve's release of its May 2-3 policy meeting minutes.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

A Pharma IPO in a Market That Loves IPOs but Hates Pharma(The 5 Minute Wrapup)

Jun 15, 2017

Tomorrow comes the IPO of Eris Lifesciences. How will a pharma IPO do in this market?

Bitcoin at $10,000?(Vivek Kaul's Diary)

Jun 14, 2017

Whether you're Venezuela or China or in India or the US...and you want to protect your wealth, you need real money. All the government has on offer is funny money.

Get Ready for Commodity Options!(Daily Profit Hunter)

Jun 16, 2017

Commodity options trading is one step closer to reality. Learn how to take advantage of this tremendous opportunity.

Walter Schloss' Investing Record(Chart Of The Day)

Jun 17, 2017

In a market full of one-hit-wonders, this investor obviously had a formula that worked. And through the think-and-thin of the market.

11 Hidden Costs Associated With Your Home Loan(Outside View)

Jun 16, 2017

Various costs associated with a home loan.

More

TRACK PFIZER

MORE ON PFIZER

PFIZER - STERLING BIOTECH COMPARISON

COMPARE PFIZER WITH

MARKET STATS